Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by Ludwig Institute for Cancer Research
Sponsor:
Collaborator:
Cancer Research Institute
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research
ClinicalTrials.gov Identifier:
NCT01810016
First received: March 8, 2013
Last updated: August 26, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2014
  Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)